Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference
Liquidia Corporation (NASDAQ: LQDA) has announced that its leadership team will participate in the 2025 Jefferies Global Healthcare Conference on June 4, 2025, at 11:05 a.m. ET in New York City. The presentation will feature CEO Dr. Roger Jeffs, CFO/COO Michael Kaseta, and CBO Jason Adair in a fireside chat format to provide business updates. Investors can access the webcast through Liquidia's website, where a recording will remain available for at least 30 days after the event.
Liquidia Corporation (NASDAQ: LQDA) ha annunciato che il suo team dirigenziale parteciperà alla 2025 Jefferies Global Healthcare Conference il 4 giugno 2025 alle 11:05 ET a New York City. La presentazione vedrà la partecipazione del CEO Dr. Roger Jeffs, del CFO/COO Michael Kaseta e del CBO Jason Adair in un formato di conversazione informale per fornire aggiornamenti aziendali. Gli investitori potranno seguire la diretta streaming tramite il sito web di Liquidia, dove la registrazione sarà disponibile per almeno 30 giorni dopo l'evento.
Liquidia Corporation (NASDAQ: LQDA) ha anunciado que su equipo directivo participará en la Conferencia Global de Salud Jefferies 2025 el 4 de junio de 2025 a las 11:05 a.m. ET en la ciudad de Nueva York. La presentación contará con el CEO Dr. Roger Jeffs, el CFO/COO Michael Kaseta y el CBO Jason Adair en un formato de charla informal para ofrecer actualizaciones comerciales. Los inversores podrán acceder a la transmisión en vivo a través del sitio web de Liquidia, donde la grabación estará disponible al menos 30 días después del evento.
Liquidia Corporation (NASDAQ: LQDA)는 2025년 6월 4일 오전 11시 5분(동부시간) 뉴욕시에서 개최되는 2025 Jefferies 글로벌 헬스케어 컨퍼런스에 경영진이 참여할 것이라고 발표했습니다. 발표에는 CEO Dr. Roger Jeffs, CFO/COO Michael Kaseta, CBO Jason Adair가 화기애애한 대화 형식으로 비즈니스 업데이트를 제공할 예정입니다. 투자자들은 Liquidia 웹사이트를 통해 웨비캐스트에 접속할 수 있으며, 녹화 영상은 행사 종료 후 최소 30일간 제공됩니다.
Liquidia Corporation (NASDAQ : LQDA) a annoncé que son équipe dirigeante participera à la Conférence mondiale Jefferies sur la santé 2025 le 4 juin 2025 à 11h05 (heure de l'Est) à New York. La présentation réunira le PDG Dr Roger Jeffs, le CFO/COO Michael Kaseta et le CBO Jason Adair dans un format de discussion informelle pour fournir des mises à jour commerciales. Les investisseurs pourront accéder au webinaire via le site de Liquidia, où l'enregistrement restera disponible pendant au moins 30 jours après l'événement.
Liquidia Corporation (NASDAQ: LQDA) hat bekannt gegeben, dass das Führungsteam am Jefferies Global Healthcare Conference 2025 am 4. Juni 2025 um 11:05 Uhr ET in New York City teilnehmen wird. Die Präsentation wird in Form eines Gespräches am Kamin mit CEO Dr. Roger Jeffs, CFO/COO Michael Kaseta und CBO Jason Adair stattfinden, um Geschäftsaktualisierungen zu geben. Investoren können den Webcast über die Website von Liquidia verfolgen, wo eine Aufzeichnung mindestens 30 Tage nach der Veranstaltung verfügbar sein wird.
- None.
- None.
MORRISVILLE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the company’s Chief Executive Officer Dr. Roger Jeffs, Chief Financial Officer and Chief Operating Officer Michael Kaseta, and Chief Business Officer Jason Adair will be providing an update on the company's business during a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday June 4, 2025, beginning at 11:05 a.m. ET, in New York City.
Access to a webcast will be available to investors and other interested parties by accessing Liquidia’s website at https://liquidia.com/investors/events-and-presentations.
An archived, recorded version of the presentation will be available on Liquidia’s website for at least 30 days following the event.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA™ (treprostinil) inhalation powder, a drug that has been approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
When is Liquidia Corporation (LQDA) presenting at the 2025 Jefferies Healthcare Conference?
Who will be presenting at the Jefferies Conference for Liquidia (LQDA)?
How can investors access Liquidia's (LQDA) presentation at the Jefferies Conference?
How long will Liquidia's (LQDA) Jefferies Conference presentation recording be available?
